We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.55 | 4.30 | 4.80 | 4.55 | 4.55 | 4.55 | 496,424 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -10.83 | 24.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/1/2019 22:58 | Mevalone is based on climactic conditions. I can understand how Jac is nervous. But that’s all I am going to say. It’s very addictive watching these posts | chrischas | |
18/1/2019 21:49 | By all means. Along with your valuation of the IP, please, and in particular the closeness to market of its immediate product launches, including, Sustaine, Cedroz, Consumer and CAP verticals, with your workings. Perhaps you could also stick in a valuation model for Mevalone, based on existing and prospective territories, as well as new applications. Together with the developing market for biopesticides. Thanks. | brucie5 | |
18/1/2019 18:12 | Jak, I'm well aware of cash situation. You seem to be unaware of the fundamental investment case, let alone proximity to break even, so I'm surprised you're here. I've invited you several times to show me your full appraisal of the opportunity, and you refuse to do this. So you're either in ignorance of it, or in denial. That is not a conversation. Unless I hear further from you in relation to the above, I will assume you are here to make mischief and place you on filter. Best, B5 | brucie5 | |
18/1/2019 17:30 | Investing, I'm not opposed to Sipcam/Sumitomo taking a bigger stake. I'd need to see the terms and reasoning before making a judgement as to it's value. I base my guess, as that is all it is, on actions in the past. I'm no doubt wildly off target, but saying that Eden has a good record of working out strategic investments like LivingBridge and Sipcam. | supersonico | |
18/1/2019 17:10 | Well personally I'd prefer stake building to begin at 50p, but... So in a sense I at least share your sentiment... | brucie5 | |
18/1/2019 16:31 | FWIW, I don't agree it would a disaster for SIPCAM to up their stake at current levels, let alone 30p; it would be thoroughly realistic. Depends how much they take of course. By looks of, 2019 may be no more than modest b/e. | brucie5 | |
18/1/2019 15:54 | Investing, Why a Disaster? It's my prediction for 2019 along with No Bayer CAP and Antoine Biron selling TT from the back of a Citroen HY Van in West Ealing. | supersonico | |
18/1/2019 15:54 | I'm trying to build a notional calendar for 2019 with key events expected. As many here, I expect this year to be key to moving the company forward, in terms of regulatory permissions (Cedroz USA), product launches (Bayer/TT), and news of Sustaine. So I'd like to invite posters to assist in building the calendar, which might be helpful to us in teasing out some of those pieces of expected news that Investing put together last year. I'll start the bidding with where we are now. Feel free to add suggestions and I'll keep an updated calendar with your attributed ideas. Jan. Trading update. 1m loss; revenue 2.8m up 48%; sales 1.6m up 100%; TT and Bayer delayed. Feb. News on TT headlice? Proactive presentation March Results published with guidance from Shore for 2019. April Bayer? May June July Aug Sept Oct Nov Dec | brucie5 | |
18/1/2019 14:06 | We (Eden) won't be around by the time Africa gets on board. | investingisatrickygame | |
18/1/2019 14:01 | Investing post 5562. edenvulnerabletoanof It's much easier to see reasons why what you suggest will happen than why it won't. It also lends itself to questions of current stakes and those stakes increasing given the market opportunity in the Medium term. | supersonico | |
18/1/2019 11:49 | Super We have way more than that to our advantage. We have IP, time and money hxxps://www.syngenta Who in agriculture, given the bio trend and barriers to entry can ignore this and Eden as soon as Sipcam/Eden announces co-encapsulation success! Eden are a steel at today's price +x. R & D time from scratch in a fast moving market and no first mover advantage will be/is a costly and potentially dangerous strategic decision if you don't have one foot in the door. # edenvulnerabletoanof | investingisatrickygame | |
18/1/2019 11:15 | I agree and think that's part of the picture but I do also think that sentiment will step change dramatically on either Catalyst news on any front be it co- encapsulation or Sustaine or other but also as the wider Sumitomo and Eastman distribution picture becomes more evident. We have the dual picture of a rapidly growing global market in biopesticides on one hand and Eden's evolving growth within that sphere on at least two fronts so far disclosed which given the maturity of the Crop protection vertical and the Sumitomo relationship could expand quiet rapidly imo. | supersonico | |
18/1/2019 10:48 | Nice little ramp on Mike Walters website this morning. Gone are the days that would positively impact Eden's share price It's simply a case of "show us the profits" before this share price is gonna rise significantly. | quazie12 | |
17/1/2019 13:15 | Expert to farmers: Pesticide misuse may cause export trouble Global markets are becoming more sensitive to the presence of pesticides in crop imports, and farmers in Saskatchewan and across Canada need to pay attention to those concerns. That was the message from Cam Dahl, president of Cereals Canada, to a crowd at the annual Crop Production Show on Monday in Saskatoon. Dahl emphasized the need for farmers to use pesticides responsibly, and follow the label directions to the letter, to avoid causing an international market disruption. “We have countries, and activists, that are looking for reasons to put up trade barriers,” he said after his presentation. “My message to farmers is we need to look at ways of ensuring that we’re not giving them the hooks to hang a trade barrier on.” He noted the rationale has already been used by Italy to erect barriers on Canadian durum wheat, which cut imports from over one million tonnes to below 400 thousand tonnes after concerns were raised over the health and safety of Canadian crops. He also pointed to the rise of protectionist populism in other European markets, and the recent trade spat between Canada and the U.S. during NAFTA negotiations. Dahl said some markets are instituting a zero-tolerance policy for the presence of certain pesticide residues, which can make the margin of error for Canadian farmers very thin since some products are measured in parts-per-billion He noted there is frustration among crop producers because Canadian farmers are typically well below the scientifically-estab But the criticism isn’t based in science, he said. “It’s impossible to meet all these demands when we move away from science,” Dahl said. “The best thing farmers can do is ensure they’re following the labelling. The right rate at the right time, following the pre-harvest interval for products that are applied in fall, ensuring glyphosate isn’t applied to green crops.” He added that farmers must not underestimate the impact of their crops on the market, no matter how small they may be. “What they do on their farm matters, and it matters to export markets,” Dahl said. “There needs to be a bigger awareness in the agriculture community that we’re not just small little bit-players … Those farm practices matter, and not just on the macro level.” ……&hel MEPs vote to increase transparency in pesticide approval | supersonico | |
17/1/2019 12:10 | Morning Northwick, Re SEE..Is a Buy imo Huge Auto and Aviation potential maturing 2020/1. share price is pants but potential is great just like here:) I'm expecting news to push this back up shortly. Hopefully Toyota. Lewbo18 on SEE Lse has a good handle on potential. Re Mevalone. Again same picture imo. Good foundations being laid short term targets don't really give a picture of global roll out potential numbers with Sumitomo/ Eastman. Stake building time now imo. TTand Bayer need further clarification. Atm it looks like the geniuses struggle to tie their own shoe laces but I expect that to change. What's curious is the Silence of the Redwings..they must be getting their berries some place else. | supersonico | |
17/1/2019 11:42 | SuperExcuse my typos . Need to go to Spec savers | northwick | |
17/1/2019 11:41 | Gm Super Your current view on 'See', if any?Re Mevalone Sales- Did Eden reach its own target for 2018 Sales? I fear not when compared to what Shore had pencilled in, which wouldn't included any singing on fee or option fees because they weren't guaranteed or secured? Your view, please | northwick |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions